BB-1701

Customer Review

Based on 1 Customer Validation

BB-1701 is an anti-HER2 antibody-drug conjugate (ADC). BB-1701 is composed of a humanized anti-HER2 antibody (Trastuzumab) (HY-P9907), a linker (Mal-PEG2-VCP), a microtubule inhibitor (Eribulin) (HY-13442), and the drug-linker conjugate for ADC is Mal-PEG2-VCP-Eribulin (HY-128870). BB-1701 has a potent cytotoxicity and bystander effects on tumors with heterogeneous target expression. BB-1701 significantly induces immunogenic cell death and the activation of the immune.

For research use only. We do not sell to patients.

  • Purity: 98.81%
  • Storage:

    -80°C, protect from light

  • Biological Activity
  • Chemical Information
  • Purity & Documentation
  • References
  • Help & FAQs
100 mg

Get Quote In-stock

Please select quantity
Amount: USD 0.00